Cunningham JW, Vaduganathan M, Claggett BL, et al. - Given sacubitril/valsartan decreases N-terminal pro–B-type natriuretic peptide (NT-proBNP) in heart failure (HF) with both reduced and preserved ejection fraction (EF), but did not afford a significant decrease in total HF hospitalizations and cardiovascular mortality, vs valsartan, among patients with HF with preserved EF (HFpEF), so, researchers assessed the prognostic worth of baseline NT-proBNP, whether NT-proBNP altered the therapeutic response to sacubitril/valsartan, as well as the treatment impact of sacubitril/valsartan on NT-proBNP overall and in key subgroups. A total of 4,796 patients experiencing HFpEF and high NT-proBNP, included in the PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial, were randomly assigned to sacubitril/valsartan or valsartan. Findings revealed that HF events were predicted by baseline NT-proBNP, but there was no influence of baseline NT-proBNP on the sacubitril/valsartan treatment effect among patients experiencing HFpEF. In both genders, and in patients with lower or higher EF, sacubitril/valsartan was shown to decrease NT-proBNP consistently.